Skip to main content
. 2016 May 10;3(4):e240. doi: 10.1212/NXI.0000000000000240

Figure 5. Increased B cell-activating factor (BAFF) levels are shared between immunomodulatory treatments.

Figure 5

(A) Plasma BAFF levels, (B) transitional B cells, (C) switched B cells, and (F) total peripheral blood mononuclear cells (PBMC) BAFF gene expression levels (RQ = relative quantity compared to housekeeping gene, with addition of n = 13 additional controls not part of the immunophenotyping cohort) were quantified in controls (CON), patients with autoimmune thyroid disease (AITD), and patients with multiple sclerosis (MS) either untreated (MS_UNT) or treated with 4 immunomodulatory treatments (interferon [IFN]–β low and IFN-β high = IFN-β low or high dose; GA = glatiramer acetate; NAT = natalizumab; FTY720 = fingolimod). Median with boxes indicating 25th and 75th percentile and whiskers indicating 1.5 × interquartile range. A linear regression with covariates age and sex was applied. Correlation between plasma BAFF levels and (D) transitional B cells and (E) switched B cells in the entire cohort after accounting for disease/treatment group, age, and sex.